Gastroesophageal Cancer – Landscape & Forecast – Disease Landscape & Forecast
The gastroesophageal cancer market—including gastric cancer, esophageal adenocarcinoma and gastroesophageal junction (GEJ) adenocarcinoma—is witnessing a substantial change, largely fueled by label expansions of immune checkpoint inhibitor therapies. The PD-1 inhibitor Opdivo (Bristol Myers Squibb) expanded its label in the United States to esophageal cancer patients and is under regulatory review, along with Keytruda (Merck & Co.), for first-line and resectable gastroesophageal cancer populations. The approval of the HER2 antibody-drug conjugate Enhertu (Daiichi Sankyo / AstraZeneca) has also expanded the treatment options for HER2-positive patients. Given the intense Phase II/III pipeline activity, we anticipate the approval of several new therapies for gastroesophageal cancer during the forecast period.
QUESTIONS ANSWERED
- How is gastroesophageal cancer segmented between specific subpopulations, and how are these defined? How does the current treatment landscape differ among esophageal cancer, gastric cancer, and GEJ adenocarcinoma patients?
- What is the expected market impact of recent drug approvals and label expansions, such as Opdivo, Keytruda and Enhertu on the various subpopulations of gastroesophageal cancer?
- Which are the most promising emerging therapies and how will they shape the future of the gastroesophageal cancer market?
- What are the drivers and constraints in the gastroesophageal cancer market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Table of contents
- Gastroesophageal Cancer - Landscape & Forecast - Disease Landscape & Forecast
- Key Updates
- Q3 2021
- September 2021
- August 2021
- July 2021
- Q2 2021
- June 2021
- May 2021
- April 2021
- Q1 2021
- March 2021
- February 2021
- January 2021
- Q4 2020
- December 2020
- Q3 2021
- Key Findings
- Market Outlook
- Key Findings
- Major-Market Share of Drug Classes in Gastroesophageal Cancer: 2019
- Major-Market Share of Drug Classes in Gastroesophageal Cancer: 2029
- Major-Market Sales of Key Therapies for Gastroesophageal Cancer: 2019-2029
- Major-Market Sales for Gastroesophageal Cancer by Population Segment: 2019-2029
- Drug-Treatable Population Share and Major-Market Sales Share in Gastroesophageal Cancer: 2019
- Drug-Treatable Population Share and Major-Market Sales Share in Gastroesophageal Cancer: 2029
- Population Positioning of Therapies in Gastroesophageal Cancer: United States and Europe
- Population Positioning of Therapies in Gastroesophageal Cancer: Japan
- Gastroesophageal Cancer SWOT Analysis
- COVID-19: Areas of Potential Forecast Impact
- COVID19: Expert insights
- Market Drivers and Constraints
- What Factors Are Driving the Market for Gastroesophageal Cancer?
- What Factors Are Constraining the Market for Gastroesophageal Cancer?
- Segment-Specific Trends
- Patient Share Dynamics of Key Players in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma in the United States: 2019-2029
- Patient Share Dynamics of Key Players in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma in Japan: 2019-2029
- Patient Share Dynamics of Key Players in Resectable Esophageal Cancer in the United States: 2019-2029
- Patient-Share Dynamics of Key Players in First-Line Metastatic HER2-Negative Gastric and Gastroesophageal Junction Adenocarcinoma in the United States: 2019-2029
- Patient-Share Dynamics of Key Players in First-Line Metastatic HER2-Negative Gastric and Gastroesophageal Junction Adenocarcinoma in Japan: 2019-2029
- Patient Share Dynamics of Key Players in First-Line Metastatic HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma in the United States: 2019-2029
- First-Line Metastatic Esophageal Cancer
- Patient-Share Dynamics of Key Players in First-Line Metastatic Esophageal Cancer in the United States: 2019-2029
- Patient-Share Dynamics of Key Players in Second- and Third-Line Metastatic Esophageal Cancer in the United States: 2019-2029
- Patient-Share Dynamics of Key Players in Third- and Fourth-Line Metastatic HER2-Negative Gastric and Gastroesophageal Junction Adenocarcinoma in the United States: 2019-2029
- Key Findings
- Forecast
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and Pathophysiology
- Disease Overview
- Disease Pathophysiology
- Anatomy of the Stomach and the Gastroesophageal Junction
- Anatomy of the Esophagus
- Histological Subtypes and Development of Gastric and Gastroesophageal Junction Adenocarcinoma
- Key Stages in the Development of Intestinal and Diffuse Types of Gastric andu00a0Gastroesophageal Junctionu00a0Adenocarcinoma
- Histological Subtypes and Development of Esophageal Cancer
- Staging and Classification
- AJCC / UICC TNM Classification System for Gastroesophageal Cancer
- AJCC / UICC Clinical Staging Classification System for Gastroesophageal Cancer
- AJCC / UICC Pathological Staging Classification System for Gastroesophageal Cancer
- AJCC / UICC Postneoadjuvant Therapy Staging Classification System for Gastroesophageal Cancer
- Key Pathways and Drug Targets
- Drug Targets and Potential Therapies for Gastroesophageal Cancer
- Drug Targets for Gastroesophageal Cancer
- Biology of Immune Checkpoint Inhibitors and Modulators
- Disease Overview
- Epidemiology
- Introduction
- Key Findings
- Epidemiology Populations
- Disease Definition
- Methods
- Sources Used for Diagnosed Incidence of Gastroesophageal Cancer
- Number of Diagnosed Incident Cases of Gastroesophageal Cancer: 2020-2030
- Definition
- Methods
- Sources Used for Stage Distribution of Gastroesophageal Cancer
- Diagnosed Incident Cases of Gastric and GEJ Adenocarcinoma by Stage Distribution: 2020-2030
- Diagnosed Incident Cases of Esophageal Adenocarcinoma by Stage Distribution: 2020-2030
- Diagnosed Incident Cases of Esophageal Squamous Cell Carcinoma by Stage Distribution: 2020-2030
- Definition
- Methods
- Sources Used for Recurrent Incidence of Gastroesophageal Cancer
- Recurrent Incident Cases of Gastroesophageal Cancer: 2020-2030
- Definition
- Methods
- Sources
- Molecular Subtype: 2020-2030
- Gastric and Gastroesophageal Junction Adenocarcinoma Patient Flow
- Drug-Treatable Cases of Gastric and Gastroesophageal Junction Adenocarcinoma: 2019-2029
- Esophageal Adenocarcinoma Patient Flow
- Drug-Treatable Cases of Esophageal Adenocarcinoma: 2019-2029
- Esophageal Squamous Cell Carcinoma Patient Flow
- Drug-Treatable Cases of Esophageal Squamous Cell Carcinoma: 2019-2029
- Drug-Treated Populations
- Drug-Treated Cases of Gastroesophageal Cancer: 2019-2029
- Introduction
- Current Treatment
- Key Findings
- Treatment Goals
- Key Endpoints Used in Clinical Trials for Gastroesophageal Cancer
- Key Current Therapies
- Overview
- Mechanism of Action of Key Current Drug Classes Used for Gastroesophageal Cancer
- Current Treatments Used for Gastroesophageal Cancer
- Market Events Impacting the Use of Key Current Therapies for Gastroesophageal Cancer
- Key Results from Select Clinical Trials Investigating Cyramza for the Treatment of Gastroesophageal Cancer
- Ongoing Clinical Development of Cyramza
- Key Ongoing Clinical Trials of Cyramza in the Treatment of Gastroesophageal Cancer
- Expert Insight: Cyramza
- Key Results from Select Clinical Trials Investigating Herceptin for the Treatment of Gastroesophageal Cancer
- Ongoing Clinical Development of Herceptin
- Expert Insight: Herceptin
- Key Results from Select Clinical Trials Investigating Enhertu for the Treatment of Gastroesophageal Cancer
- Ongoing Clinical Development of Enhertu
- Key Ongoing Clinical Trials of Enhertu in the Treatment of Gastroesophageal Cancer
- Expert Insight: Enhertu
- Key Results From Select Clinical Trials Investigating Keytruda for the Treatment of Gastroesophageal Cancer
- Ongoing Clinical Development of Keytruda
- Key Ongoing Clinical Trials of Keytruda in the Treatment of Gastroesophageal Cancer
- Expert Insight: Keytruda
- Key Results From Select Clinical Trials Investigating Opdivo for the Treatment of Gastroesophageal Cancer
- Ongoing Clinical Development of Opdivo
- Key Ongoing Clinical Trials of Opdivo in the Treatment of Gastroesophageal Cancer
- Expert Insight: Opdivo
- Lonsurf
- Key Results from Select Clinical Trials Investigating Lonsurf for the Treatment of Gastroesophageal Cancer
- Ongoing Clinical Development of Lonsurf
- Expert Insights: Lonsurf
- Medical Practice
- Localized and Resectable Locally Advanced Gastroesophageal Cancer
- Unresectable Locally Advanced Gastroesophageal Cancer
- First-Line Metastatic Gastroesophageal Cancer
- Second-Line Gastroesophageal Cancer
- Third- and Fourth-Line Metastatic Gastroesophageal Cancer
- Patient Characteristics Influencing Drug Selection in Gastroesophageal Cancer
- Region-Specific Treatment Practices
- Treatment Decision Tree for Locally Advanced and Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: United States
- Treatment Decision Tree for Locally Advanced and Metastatic Esophageal Cancer: United States
- Treatment Decision Tree for Locally Advanced and Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: Europe
- Treatment Decision Tree for Locally Advanced and Metastatic Esophageal Cancer: Europe
- Treatment Decision Tree for Locally Advanced and Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: Japan
- Treatment Decision Tree for Locally Advanced and Metastatic Esophageal Cancer: Japan
- Key Findings
- Unmet Need Overview
- Current and Future Attainment of Unmet Needs in Gastroesophageal Cancer
- Top Unmet Needs in Gastroesophageal Cancer: Current and Future Attainment
- Emerging Therapies
- Key Findings
- Key Emerging Therapies
- Key Therapies in Development for Gastroesophageal Cancer
- Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Gastroesophageal Cancer
- Key Results From Select Clinical Trials Investigating Bavencio for the Treatment of Gastroesophageal Cancer
- Analysis of Clinical Development Program for Bavencio
- Expert Insight: Bavencio
- Expectations for Market Authorization and Sales Opportunity of Bavencio in Gastroesophageal Cancer
- Key Results From Select Clinical Trials Investigating Tislelizumab for the Treatment of Gastroesophageal Cancer
- Key Ongoing Clinical Trials of Tislelizumab in the Treatment of Gastroesophageal Cancer
- Analysis of Clinical Development Program for Tislelizumab
- Expert Insight: Tislelizumab
- Expectations for Market Authorization and Sales Opportunity of Tislelizumab in Gastroesophageal Cancer
- Key Results From Select Clinical Trials Investigating Imfinzi for the Treatment of Gastroesophageal Cancer
- Key Ongoing Clinical Trials of Imfinzi in the Treatment of Gastroesophageal Cancer
- Analysis of Clinical Development Program for Imfinzi
- Expectations for Market Authorization and Sales Opportunity of Imfinzi in Gastroesophageal Cancer
- Key Results From Select Clinical Trials Investigating Tecentriq for the Treatment of Gastroesophageal Cancer
- Key Ongoing Clinical Trials of Tecentriq in the Treatment of Gastroesophageal Cancer
- Analysis of Clinical Development Program for Tecentriq
- Expectations for Market Authorization and Sales Opportunity of Tecentriq in Gastroesophageal Cancer
- Analysis of Clinical Development Program for Tiragolumab
- Expectations for Market Authorization and Sales Opportunity of Tiragolumab in Gastroesophageal Cancer
- Key Results From Select Clinical Trials Investigating Tyvyt for the Treatment of Gastroesophageal Cancer
- Key Ongoing Clinical Trials of Tyvyt in the Treatment of Gastroesophageal Cancer
- Analysis of Clinical Development Program for Tyvyt
- Expectations for Market Authorization and Sales Opportunity of Tyvyt in Gastroesophageal Cancer
- Key Results From Select Clinical Trials Investigating Margetuximab for the Treatment of Gastroesophageal Cancer
- Key Ongoing Clinical Trials of Margetuximab in the Treatment of Gastroesophageal Cancer
- Analysis of Clinical Development Program for margetuximab
- Expert Insight: Margetuximab
- Expectations for Market Authorization and Sales Opportunity of Margetuximab in Gastroesophageal Cancer
- Tukysa
- Key Ongoing Clinical Trials of Tukysa in the Treatment of Gastroesophageal Cancer
- Analysis of Clinical Development Program for Tukysa
- Expectations for Market Authorization and Sales Opportunity of Tukysa in Gastroesophageal Cancer
- Key Results From Select Clinical Trials Investigating Rivoceranib for the Treatment of Gastroesophageal Cancer
- Analysis of Clinical Development Program for Rivoceranib
- Expert Insight: Rivoceranib
- Expectations for Market Authorization and Sales Opportunity of Rivoceranib in Gastroesophageal Cancer
- Key Results From Select Clinical Trials Investigating Stivarga for the Treatment of Gastroesophageal Cancer
- Key Ongoing Clinical Trials of Stivarga in the Treatment of Gastroesophageal Cancer
- Analysis of Clinical Development Program for Stivarga
- Expert Insight: Stivarga
- Expectations for Market Authorization and Sales Opportunity of Stivarga in Gastroesophageal Cancer
- Key Results From Select Clinical Trials Investigating Lenvima for the Treatment of Gastroesophageal Cancer
- Key Ongoing Clinical Trials of Lenvima in the Treatment of Gastroesophageal Cancer
- Analysis of the Clinical Development Program for Lenvima
- Expectations for Market Authorization and Sales Opportunity of Lenvima in Gastroesophageal Cancer
- Key Ongoing Clinical Trials of Pamiparib in the Treatment of Gastroesophageal Cancer
- Analysis of Clinical Development Program for Pamiparib
- Expert Insight: Pamiparib
- Expectations for Market Authorization and Sales Opportunity of Pamiparib in Gastroesophageal Cancer
- Key Results From Select Clinical Trials Investigating TAS-118 for the Treatment of Gastroesophageal Cancer
- Analysis of Clinical Development Program for TAS-118
- Expert Insight: TAS-118
- Expectations for Market Authorization and Sales Opportunity of TAS-118 in Gastroesophageal Cancer
- Key Results From Select Clinical Trials Investigating Zolbetuximab for the Treatment of Gastroesophageal Cancer
- Key Ongoing Clinical Trials of Zolbetuximab in the Treatment of Gastroesophageal Cancer
- Analysis of Clinical Development Program for Zolbetuximab
- Expert Insight: Zolbetuximab
- Expectations for Market Authorization and Sales Opportunity of Zolbetuximab in Gastroesophageal Cancer
- Bemarituzumab
- Key Results From Select Clinical Trials Investigating Bemarituzumabu00a0for the Treatment of Gastroesophageal Cancer
- Analysis of Clinical Development Program for Bemarituzumabu00a0
- Expert Insight: Bemarituzumab
- Expectations for Market Authorization and Sales Opportunity of Bemarituzumab in Gastroesophageal Cancer
- Early-Phase Pipeline Analysis
- Select Compounds in Early-Phase Development for Gastroesophageal Cancer
- Key Findings
- Access and Reimbursement Overview
- Region-Specific Reimbursement Practices
- Key Market Access Considerations in Gastroesophageal Cancer: United States
- General Reimbursement Environment: United States
- Key Market Access Considerations in Gastroesophageal Cancer: EU5
- General Reimbursement Environment: EU5
- Key Market Access Considerations in Gastroesophageal Cancer: Japan
- General Reimbursement Environment: Japan
- Region-Specific Reimbursement Practices
- Appendix
- Gastroesophageal Cancer Bibliography
- Key Updates
Fiona Wiegert, M.Sc., is a business insights analyst on the Oncology team at Clarivate. She has a background in market research and analysis within the pharmaceutical industry and experience in several oncology indications. Previously, she worked on product-specific business cases and forecast models at Accord Healthcare. She earned a master’s degree in cognitive neuroscience from the University of Sussex and was awarded the prize for best performance on this course.